fbpx
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore exercitation ullamco…

Innovations in Regenerative and Therapeutic Biologics

Learn more

1,000,000 ALLOGRAFTS DISTRIBUTED

MiMedx has distributed more than 1 million allografts to date with zero reported adverse reactions attributed to our products.

2017 FORTUNE MAGAZINE 5TH FASTEST GROWING PUBLIC COMPANY

MiMedx was named #5 on Fortune Magazine’s Top 100 Fastest Growing Companies of 2017.

USP NATIONAL FORMULARY MONOGRAPH ON DHACM PRODUCTS

MiMedx dHACM is the first amnion/chorion dehydrated membrane to be described in a USP monograph.

The MiMedx Difference

Our Products

Investors

MiMedx is a high growth biopharmaceutical company that is unique, as we deliver strong financial performance that will allow us to fuel future growth. Since 2012, MiMedx has been profitable on an Adjusted EBITDA basis. This financial performance allows the company to make investments in areas that build sustainable competitive advantages in our targeted markets while avoiding the dilutive impacts of raising additional capital.